We will rely on you to help lend your voice and support the biotechnology industry.
Learn more about BIO initiatives to advance the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO CEO & Investor Conference
February 12-13, 2018
BIO IP Counsels Committee Conference
April 11-13, 2018
BIO Industry Analysis Reports
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
July 16 - 19, 2018 | Philadelphia, Pennsylvania
Before joining AMSilk, Mr. Klein worked for Evonik Industries AG. In 2011 Evonik acquired nanoresins AG and Hanse Chemie AG. Mr Klein served as a member of the Managing Board of both companies since 2006. In this function he significantly contributed to the growth of the enterprises, the integration of new technologies and the optimization of the production processes as well as the strategic expansion of the distribution network in different countries. Both companies are internationally operating enterprises that develop, produce and sell on a worldwide basis high-quality and innovative performance materials and additives for industrial applications.
Prior, Mr. Klein was a member of the Managing Board of Directors of the holding company Mulligan BioCapital AG, Hamburg and Munich. Mulligan invested in medical technology, bio-tech and high-tech enterprises in the US and Europe for many years. At Mulligan, Mr. Klein among other things played a key role in two initial public offerings of portfolio companies at NASDAQ, one initial public offering at Prime Standard in Frankfurt as well as trade sales to strategic investors. Before joining Mulligan, he was with Fresenius AG, Bad Homburg where he headed subsidiaries as CEO or CFO.
Mr. Klein is a graduate of the University of Mannheim (business school graduate) and has an MBA of the Zicklin School of Business, City University of New York.
This speaker's sessions: